2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapyEyebrow and Eyelash Loss in Patients With Cancer.
Rose L, Khuhro A, Minta A, Novice M, Novice T, Lustberg M, Ruddy K, Rake E, Loprinzi C, Dulmage B. Eyebrow and Eyelash Loss in Patients With Cancer. Journal Of Drugs In Dermatology 2024, 23: 327-331. PMID: 38709698, DOI: 10.36849/jdd.8003.Peer-Reviewed Original ResearchConceptsPrevention optionsRadiation therapyTopical vasoconstrictorEndocrine therapyEyelash lossTreatment optionsPrescription medicationsCancer treatmentPatientsScalp coolingHair lossRobust researchMadarosisPermanent tattoosTherapyCancerTreatmentEyebrowsEyelash hairScalpOptionsChemotherapyCryotherapyVasoconstrictorDermatologists
2023
Hair loss during and after breast cancer therapy
Rose L, Lustberg M, Ruddy K, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Supportive Care In Cancer 2023, 31: 186. PMID: 36826602, DOI: 10.1007/s00520-023-07634-5.Peer-Reviewed Original ResearchConceptsTreatment optionsHair lossDistressing side effectsChemotherapy-induced alopeciaCancer therapyBreast cancer therapyEndocrine therapyMajor surgeryPatient counselingTelogen effluviumBreast cancerBreast oncologistsSide effectsPrevention strategiesAlopeciaTherapyChemotherapyPatientsSurgeryOncologistsOptionsEtiologyCancer
2022
Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?
Williams N, Grimm M, Gast K, Lustberg M. Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today? Current Breast Cancer Reports 2022, 14: 142-152. DOI: 10.1007/s12609-022-00463-1.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancerSystemic therapyClinical outcomesER-positive breast cancerTriple-negative breast cancerBreast cancer supportRobust clinical outcomesOptimized clinical outcomesQuality of lifePersonalized medicine approachNeoadjuvant regimensAdditional therapyEndocrine therapySelect patientsClinical trialsBest therapyPrognostic biomarkerPatientsCancer supportTherapyMedicine approachCancerRoutine useGenomic testing
2021
316P Attitudes towards the use of stereotactic body radiation therapy in oligometastatic breast cancer: Results of an OncoAlert survey
Vukovic P, Meattini I, Lambertini M, de Azambuja E, Prat A, Aftimos P, Lustberg M, Kruljac I, Morgan G. 316P Attitudes towards the use of stereotactic body radiation therapy in oligometastatic breast cancer: Results of an OncoAlert survey. Annals Of Oncology 2021, 32: s502-s503. DOI: 10.1016/j.annonc.2021.08.599.Peer-Reviewed Original ResearchTreating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series
Blow T, Hyde PN, Falcone JN, Neinstein A, Vasan N, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Integrative Cancer Therapies 2021, 20: 15347354211032283. PMID: 34259084, PMCID: PMC8283040, DOI: 10.1177/15347354211032283.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerSodium-glucose co-transporter-2 inhibitorsLow-carbohydrate dietCase seriesCarbohydrate dietHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Sodium-Glucose CoTransporter 2 inhibitorsTarget adverse effectsFactor receptor 2Postmenopausal womenTreatment delayPharmacologic interventionsBreast cancerDose reductionReceptor 2HyperglycemiaTreatment efficacyHormone receptorsAdverse effectsAlpelisibSelective phosphatidylinositolTherapy
2020
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar AA, Selby LV, Lustberg MB, Pawlik TM. Surgical Management of Breast Cancer Liver Metastasis. Surgical Oncology Clinics Of North America 2020, 30: 27-37. PMID: 33220807, DOI: 10.1016/j.soc.2020.09.003.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesCancer liver metastasesSystemic chemotherapyHepatic resectionLiver metastasesAblative therapyProlonged disease-free intervalDisease-free intervalBetter overall survivalLong-term outcomesLocal-regional therapyEffective systemic chemotherapyBreast cancer metastasisLimited diseaseOverall survivalRegional therapySurgical managementSurgery benefitMultidisciplinary settingPatientsCancer metastasisMetastasisTherapyResectionChemotherapy
2015
Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach
Reinbolt R, Mangini N, Hill J, Levine L, Dempsey J, Singaravelu J, Koehler K, Talley A, Lustberg M. Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. Seminars In Oncology Nursing 2015, 31: 146-155. PMID: 25951743, DOI: 10.1016/j.soncn.2015.02.002.Peer-Reviewed Original ResearchConceptsEndocrine therapyBreast cancerMetastatic breast cancer settingLong-term disease outcomesHormone-positive breast cancerBreast cancer settingPositive breast cancerNeoadjuvant therapyTherapy adherenceClinical guidelinesSymptom interventionCancer settingDisease outcomeClinical considerationsOptimal durationNursing practiceTherapyCancerAdditional researchPivotal roleTreatmentNational statisticsNeoadjuvantAdjuvantSymptoms
2012
Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy
Garcia-Villa A, Balasubramanian P, Miller B, Lustberg M, Ramaswamy B, Chalmers J. Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy. Frontiers In Oncology 2012, 2: 128. PMID: 23112954, PMCID: PMC3480704, DOI: 10.3389/fonc.2012.00128.Peer-Reviewed Original ResearchStage IV breast cancerTumor cellsBreast cancer patientsPlatinum-based therapySolid tumor malignanciesPotential of CTCsSurface markers CD45Γ-H2AXDNA-damaging therapiesΓ-H2AX levelsPlatinum therapyPeripheral bloodCancer patientsPredictive markerPatient outcomesPrognostic markerBreast cancerΓ-H2AX stainingPatient's conditionTumor malignancyTherapyNegative depletionLiquid biopsyStaining patternCell apoptosis